Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Fundamental & Clinical Pharmacology Année : 2024

Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network

Pauline Gandolfo
  • Fonction : Auteur
Thomas Soeiro
  • Fonction : Auteur
Elisabeth Jouve
  • Fonction : Auteur
Bruno Revol
  • Fonction : Auteur
Celian Bertin
  • Fonction : Auteur
Celine Eiden
  • Fonction : Auteur
Valerie Gibaja
  • Fonction : Auteur
Leila Chaouachi
  • Fonction : Auteur
Marie-Christine Perault-Pochat
  • Fonction : Auteur
Cecile Chevallier
  • Fonction : Auteur
Aurelie Aquizerate
  • Fonction : Auteur
Reynald Le Boisselier
  • Fonction : Auteur
Louise Carton
  • Fonction : Auteur
Maryse Lapeyre-Mestre
  • Fonction : Auteur
Elisabeth Frauger
  • Fonction : Auteur
Clemence Lacroix
  • Fonction : Auteur
Joelle Micallef
  • Fonction : Auteur

Résumé

BACKGROUND: Due to its psychoactive effects, ketamine has become a drug used for non-medical purpose. OBJECTIVES: To assess the latest trends in ketamine use among people with substance use disorder and to characterize its clinical complications using complementary health data sources of the French Addictovigilance Network. METHODS: First, we extracted all reports involving ketamine from 2012 to 2021 from the database of the OPPIDUM program (i.e., a multicentric program conducted in collaboration with hundreds of substance abuse treatment facilities that collects data on drugs used by subjects with substance use disorders). We described the reports globally and the changes from 2012 to 2021. Second, we extracted all cases involving ketamine from July 2020 to December 2022 from the French National Pharmacovigilance Database (BNPV). We identified the cases related to ketamine use among people with substance use disorder and described them. RESULTS: There was a 2.5-fold increase in the number of ketamine users with substance use disorder in the OPPIDUM program, from 35 (0.7%) subjects in 2012 to 89 (1.7%) subjects in 2021. There was an increase in the proportion of subjects who were daily users, had distress upon discontinuation, and presented addiction. There were 238 cases related to ketamine use among people with substance use disorder in the French National Pharmacovigilance Database from July 2020 to December 2022. Among them, 94 (39.5%) cases involved ketamine use disorder, 20 (8.4%) cases involved urinary tract and kidney symptoms, and 13 (5.5%) cases involved hepatobiliary symptoms. CONCLUSION: The trend observed over 10 years reflects the growth in ketamine use among people with substance use disorder, although it does not allow to estimate the rates of non-medical use of ketamine in the general population. Ketamine-induced uropathy and cholangiopathy are reported in ketamine users with substance use disorder, especially in case of repeated and/or prolonged use of high doses.
Fichier principal
Vignette du fichier
BPH_FundamClinPharmacol_2024_Gandolfo.pdf (1.34 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04502174 , version 1 (13-03-2024)

Licence

Paternité

Identifiants

Citer

Pauline Gandolfo, Thomas Soeiro, Elisabeth Jouve, Bruno Revol, Amelie Daveluy, et al.. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network. Fundamental & Clinical Pharmacology, 2024, ⟨10.1111/fcp.12995⟩. ⟨hal-04502174⟩

Collections

U1219
0 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More